

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2015 OS WB

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B44, B57, Cw5, Cw6; DR4, DR15, DQ6, DQ8

Summary of Results								
PBL/T-Cells					B-Cells			
Total tested	20	19	20	20	18	17	18	18
Positive	1	7	0	0	18	5	0	3
Negative	19	12	20	20	0	12	18	15
NT/Equivocal	2	3	2	2	1	2	1	1
% Positive	5.0%	36.8%	0.0%	0.0%	100.0%	29.4%	0.0%	16.7%
% Negative	95.0%	63.2%	100.0%	100.0%	0.0%	70.6%	100.0%	83.3%
Consensus	Negative	Not Assessed	Negative	Negative	Positive	Not Assessed	Negative	Negative
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17	B51
Without DTT					Without DTT			
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
101	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
114	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
117	NT	NT	NT	NT				
126	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
136	Negative	Negative	Negative	Negative				
145	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
149	Negative	Negative	Negative	Negative				
162	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive
163	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
169	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive
186	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative
204	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
206	Negative	Positive	Negative	Negative	Positive	Negative	Negative	Negative
210	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative
227	Negative	NT	Negative	Negative	Positive	NT	Negative	Negative
235	NT	NT	NT	NT	NT	NT	NT	NT
243	Negative	Positive	Negative	Negative	Positive	Negative	Negative	Negative
262	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative
268	Negative	Positive	Negative	Negative	Positive	Negative	Negative	Negative
284	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative
311	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive
315	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative

Late delivery of samples

Serum 2 - technical failure
Late delivery of samples

There were delivery issues for several laboratories for samples 2A01&02/2015, due to delays with customs. This should not impact future distributions.

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2015 OS WB

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					6					100	100
114	1	2	1	1	8	1	1	2			
117	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
126	50%				100%					80	100
136	1	1	1	2						95	
145					6-8					100	100
149									85		
162		6/8			8	6/8		6		100	100
163	1	1	1	1	8	1	1	1		80	85
169	1	1	1	1	8	1	1	2		97	98
186	0	6	0	0	6	6	0	0		90	90
204	4	4	4	4	8	6	6	6		50	30
206	1	6	1	1	8	1	1	1		100	100
210	0	0	0	0	+++	0	0	0		90	80
227		NT			8	NT				95	95
235	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
243	2	weak	2	2	weak	2	2	2	90	80	80
262	1	1	1	1	8	4	1	1	80	70	70
268	1	6	1	1	8	1	1	1		90	80
284	1	6	1	1	8	4	1	2		98	95
311	1	8	1	1	8	4	1	4		95	95
315	1	1	1	1	8	1	1	1		100	100

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2015 OS WB

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B44, B57, Cw5, Cw6; DR4, DR15, DQ6, DQ8

Summary of Results									
PBL/T-Cells					B-Cells				
Total tested	16	15	16	16	14	14	15	15	
Positive	0	6	0	0	14	6	0	0	
Negative	16	9	16	16	0	8	15	15	
NT/Equivocal	1	2	1	1	1	2	1	1	
% Positive	0.0%	40.0%	0.0%	0.0%	100.0%	42.9%	0.0%	0.0%	
% Negative	100.0%	60.0%	100.0%	100.0%	0.0%	57.1%	100.0%	100.0%	
Consensus	Negative	Not Assessed	Negative	Negative	Positive	Not Assessed	Negative	Negative	
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17	B51	
With DTT					With DTT				
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
114	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
149	Negative	Negative	Negative	Negative					
162	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
163	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
186	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
204	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
206	Negative	Positive	Negative	Negative	Positive	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
227	Negative	NT	Negative	Negative	Positive	NT	Negative	Negative	
235	NT	NT	NT	NT	NT	NT	NT	NT	
262	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
268	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
284	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
311	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
315	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

Serum 2 - technical failure
Late delivery of samples

There were delivery issues for several laboratories for samples 2A01&02/2015, due to delays with customs. This should not impact future distributions.

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2015 OS WB

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					8					100	100
114	1	1	1	1	8	1	1	1			
149									85		
162		6/8			8	6				100	100
163	1	1	1	1	8	1	1	1		80	85
169	1	1	1	1	8	1	1	1		97	98
186	0	6	0	0	6	6	0	0		90	90
204	4	4	4	4	8	6	6	6		50	30
206	1	6	1	1	8	1	1	1		100	100
210	0	0	0	0	+++	0	0	0		90	80
227		NT			8	NT				95	95
235	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
262	1	1	1	1	8	4	1	1	80	70	70
268	1	6	1	1	8	6	1	1		90	80
284	1	8	1	1	8	6	1	1		98	95
311	1	8	1	1	8	4	1	1		95	95
315	1	1	1	1	8	1	1	1		100	100